Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%
CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO | NVO Price Prediction) now offers a more compelling setup than GLP-1 category…